Although radiotherapy is a well-established treatment modality for both solid and liquid tumors, its utility in the management of benign diseases remains poorly elucidated. In general, oncologists and non-oncologic specialists in the U.S.

This activity covers updates and evolving data in treating biochemically recurrent prostate cancer post-prostatectomy. One speaker covers fractionation: can we safely hypofractionate in the post-operative setting, or is the data more supportive of conventional fractionation?

Numerous randomized trials have studied the benefit of adding androgen deprivation therapy (ADT) and/or prolonging its duration when treating localized prostate cancer with radiotherapy, while other trials have interrogated the benefit of escalating radiotherapy dose itself.

A subset of patients with limited metastatic cancer coined oligometastatic disease can benefit from aggressive local therapy, such as SABR, thus prolong survival by eradicating all sites of visible cancer.

Despite the increasing recognition of the long-term effects of radiation therapy on pelvic health, many healthcare providers remain inadequately trained to address these specific issues.

The management of patients with grade 2 – 3 glioma has recently become even more complicated due to incorporation of molecular findings for pathologic diagnosis, changing criteria for who is considered high risk, and variability in the use and choice of chemotherapy with radiotherapy.

With improved systemic therapy, the management of brain metastasis has become increasingly important. A number of immunotherapies and targeted agents have shown blood brain barrier penetration with a potential role in the upfront management of brain metastases and leptomeningeal disease.